NASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free KRON Stock Alerts $1.00 +0.02 (+2.04%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.96▼$1.0250-Day Range$0.95▼$1.3852-Week Range$0.73▼$2.29Volume437,697 shsAverage Volume310,599 shsMarket Capitalization$60.10 millionP/E RatioN/ADividend YieldN/APrice Target$4.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kronos Bio alerts: Email Address Kronos Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside325.0% Upside$4.25 Price TargetShort InterestHealthy1.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$7,736 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.74) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector304th out of 908 stocksPharmaceutical Preparations Industry136th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingKronos Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKronos Bio has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.65% of the float of Kronos Bio has been sold short.Short Interest Ratio / Days to CoverKronos Bio has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kronos Bio has recently decreased by 0.35%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKronos Bio does not currently pay a dividend.Dividend GrowthKronos Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRON. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Kronos Bio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for KRON on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Kronos Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kronos Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,736.00 in company stock.Percentage Held by Insiders23.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kronos Bio are expected to grow in the coming year, from ($1.74) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kronos Bio is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kronos Bio is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKronos Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Kronos Bio Stock (NASDAQ:KRON)Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.Read More KRON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRON Stock News HeadlinesApril 25, 2024 | americanbankingnews.comKronos Bio (NASDAQ:KRON) Trading 1.1% Higher April 24, 2024 | globenewswire.comKronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 31, 2024 | msn.com5 Boutique Fitness Studios in Bangkok for an Elevated Workout ExperienceMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)March 21, 2024 | benzinga.comRecap: Kronos Bio Q4 EarningsMarch 21, 2024 | msn.comKronos Bio reports Q4 resultsMarch 21, 2024 | investorplace.comKRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 21, 2024 | globenewswire.comKronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 | seekingalpha.comKRON Kronos Bio, Inc.March 8, 2024 | bizjournals.comCancer drug developer Kronos Bio slashes staffing for 2nd time in 4 monthsMarch 7, 2024 | marketwatch.comKronos Bio to Cut About 21% of WorkforceMarch 7, 2024 | globenewswire.comKronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayMarch 5, 2024 | globenewswire.comKronos Bio To Present Three Posters at AACR 2024 Annual MeetingFebruary 27, 2024 | globenewswire.comKronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceFebruary 27, 2024 | finance.yahoo.comKronos Bio, Inc. (KRON)February 26, 2024 | finance.yahoo.comKRON Mar 2024 2.500 putFebruary 22, 2024 | edition.cnn.comKronos Bio IncFebruary 21, 2024 | msn.comSingle Pass’ biopsy device completes initial live clinical cases in ItalyFebruary 21, 2024 | finance.yahoo.comGroundbreaking Live Clinical Cases Completed with the Single Pass KRONOS Biopsy Closure DeviceJanuary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kronos Bio Amid Restructuring and Promising KB-0742 Clinical DataJanuary 25, 2024 | msn.comKronos Bio streamlines leadership, cuts CMO,CSO and COO rolesJanuary 25, 2024 | finance.yahoo.comKronos Bio Implements New Leadership Structure to Drive Pipeline AdvancementDecember 20, 2023 | finanznachrichten.deKronos Bio, Inc.: Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateDecember 19, 2023 | benzinga.comKronos Bio Stock (NASDAQ:KRON), Analyst Ratings, Price Targets, PredictionsDecember 19, 2023 | markets.businessinsider.comKronos Bio Receives Buy Rating from Analyst Amid Promising Pipeline DevelopmentsSee More Headlines Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/26/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRON CUSIPN/A CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Target$4.25 High Stock Price Target$6.00 Low Stock Price Target$2.50 Potential Upside/Downside+325.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,670,000.00 Net Margins-1,791.87% Pretax Margin-1,791.87% Return on Equity-58.79% Return on Assets-45.03% Debt Debt-to-Equity RatioN/A Current Ratio7.24 Quick Ratio7.24 Sales & Book Value Annual Sales$6.29 million Price / Sales9.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.37Miscellaneous Outstanding Shares60,100,000Free Float46,033,000Market Cap$60.10 million OptionableOptionable Beta1.82 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Norbert W. Bischofberger Ph.D. (Age 68)President, CEO & Director Comp: $809.7kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Comp: $40kMs. Sandra A. Gardiner (Age 58)Interim CFO & Principal Accounting Officer Dr. Margaux Bennett Ph.D.Vice President of Corporate Development & Investor RelationsMs. Allison Frisbee J.D. (Age 41)Senior Vice President of Corporate Operations & Legal Dr. Charles Lin Ph.D. (Age 39)Senior Vice President of Research & Development Dr. Elizabeth A. Olek D.O. (Age 59)M.P.H., Senior Vice President of Clinical Development Mr. Wes Trotter Ph.D.Senior Vice President of Drug Discovery & Pharmaceutical DevelopmentMs. Rocio Martin HoyosSenior Vice President of Corporate Strategy & Portfolio ManagementMore ExecutivesKey CompetitorsReneo PharmaceuticalsNASDAQ:RPHMSCYNEXISNASDAQ:SCYXGain TherapeuticsNASDAQ:GANXHomology MedicinesNASDAQ:FIXXKezar Life SciencesNASDAQ:KZRView All CompetitorsInsidersElizabeth A OlekSold 7,368 sharesTotal: $7,736.40 ($1.05/share)Barbara KosaczSold 10,676 sharesTotal: $12,597.68 ($1.18/share)Jorge DimartinoSold 12,009 sharesTotal: $14,170.62 ($1.18/share)Christopher DinsmoreSold 7,366 sharesTotal: $8,691.88 ($1.18/share)Jorge DimartinoSold 17,367 sharesTotal: $22,577.10 ($1.30/share)View All Insider Transactions KRON Stock Analysis - Frequently Asked Questions Should I buy or sell Kronos Bio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRON shares. View KRON analyst ratings or view top-rated stocks. What is Kronos Bio's stock price target for 2024? 2 analysts have issued 1-year target prices for Kronos Bio's stock. Their KRON share price targets range from $2.50 to $6.00. On average, they predict the company's share price to reach $4.25 in the next year. This suggests a possible upside of 325.0% from the stock's current price. View analysts price targets for KRON or view top-rated stocks among Wall Street analysts. How have KRON shares performed in 2024? Kronos Bio's stock was trading at $1.25 at the start of the year. Since then, KRON stock has decreased by 20.0% and is now trading at $1.00. View the best growth stocks for 2024 here. When is Kronos Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our KRON earnings forecast. How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) announced its earnings results on Thursday, March, 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The business had revenue of $2.29 million for the quarter, compared to analysts' expectations of $1.50 million. Kronos Bio had a negative net margin of 1,791.87% and a negative trailing twelve-month return on equity of 58.79%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $175 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Kronos Bio? Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRON) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
